Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis
Article 2010 en
Authors
IE
I.J. van den Elskamp
BB
Barry P. Boden
VD
Vincenzo Dattola
Abstract
1 min read
Within a 6-month period, significant atrophy can be detected and on-study associations of PBVC and PBHs emphasizes axonal loss to be a driving mechanism. Application as primary outcome measure in short-term clinical trials with feasible sample size requires a potent drug to obtain sufficient power.
IJ van den Elskamp, DL Knol, Hugo Vrenken, Giorgos B. Karas, A. Meijerman, Massimo Filippi, Ludwig Kappos, Franz Fazekas, K. Wagner, Christopher Pohl, Rupert Sandbrink, CH Polman, Bernard M.J. Uitdehaag, Frederik Barkhof
Marco Rovaris, Anna Gambini, Antonio Gallo, Andrea Falini, Angelo Ghezzi, Béatrice Benedetti, Maria Pia Sormani, Vittorio Martinelli, Giancarlo Comi, Massimo Filippi
P. D. Molyneux, Ludwig Kappos, Chris H. Polman, Carlo Pozzilli, Frederik Barkhof, Massimo Filippi, Tarek Yousry, David W. Hahn, Klaus Wagner, Mahdiyeh Khabbaz Koche Ghazi, K. Beckmann, Frank Dahlke, Nicholas Losseff, Gareth J. Barker, Alan J. Thompson, D. H. Miller
Arman Eshaghi, Razvan Marinescu, Alexandra L. Young, Nicholas C. Firth, Ferrán Prados, M. Jorge Cardoso, Carmen Tur, Floriana De Angelis, Niamh Cawley, Wallace Brownlee, Nicola De Stefano, Maria Laura Stromillo, Marco Battaglini, Serena Ruggieri, Claudio Gasperini, Massimo Filippi, Maria A. Rocca, Àlex Rovira, Jaume Sastre‐Garriga, Jeroen J.G. Geurts, Hugo Vrenken, Viktor Wottschel, Cyra E Leurs, Bernard M.J. Uitdehaag,
Gordon Ingle, Valerie L. Stevenson, David H. Miller, Siobhan M Leary, Marco Rovaris, Frederik Barkhof, Bruno Brochet, Vincent Dousset, Massimo Filippi, Xavier Montalbán, Nynke F. Kalkers, CH Polman, Àlex Rovira, Alan J. Thompson
Discussion(0)
No comments yet. Be the first to comment.